Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Bacterial RNA polymerase can retain σ70 throughout transcription.

Harden TT, Wells CD, Friedman LJ, Landick R, Hochschild A, Kondev J, Gelles J.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):602-7. doi: 10.1073/pnas.1513899113. Epub 2016 Jan 5.

PMID:
26733675
2.

Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.

Gupta R, Geiter LJ, Hafkin J, Wells CD.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1261-2. doi: 10.5588/ijtld.15.0541. No abstract available.

PMID:
26459547
3.

The primary σ factor in Escherichia coli can access the transcription elongation complex from solution in vivo.

Goldman SR, Nair NU, Wells CD, Nickels BE, Hochschild A.

Elife. 2015 Sep 15;4. doi: 10.7554/eLife.10514.

4.

Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.

He R, Yu ZH, Zhang RY, Wu L, Gunawan AM, Lane BS, Shim JS, Zeng LF, He Y, Chen L, Wells CD, Liu JO, Zhang ZY.

ACS Med Chem Lett. 2015 Jun 8;6(7):782-6. doi: 10.1021/acsmedchemlett.5b00118. eCollection 2015 Jul 9.

PMID:
26191366
5.

Delamanid for Extensively Drug-Resistant Tuberculosis.

Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H.

N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. No abstract available.

6.

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.

PMID:
25982816
7.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

8.

Primary cilia signaling mediates intraocular pressure sensation.

Luo N, Conwell MD, Chen X, Kettenhofen CI, Westlake CJ, Cantor LB, Wells CD, Weinreb RN, Corson TW, Spandau DF, Joos KM, Iomini C, Obukhov AG, Sun Y.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12871-6. doi: 10.1073/pnas.1323292111. Epub 2014 Aug 20.

9.

Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, Kapur R, Wells CD, Zhang ZY.

J Med Chem. 2014 Aug 14;57(15):6594-609. doi: 10.1021/jm5006176. Epub 2014 Jul 28.

10.

Response to letter to the editor.

Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD.

Pain. 2014 May;155(5):1045-6. doi: 10.1016/j.pain.2014.01.029. Epub 2014 Feb 7. No abstract available.

PMID:
24513276
11.

Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.

Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, Hudmon A, Wells CD.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17368-73. doi: 10.1073/pnas.1308236110. Epub 2013 Oct 7.

12.

Interventional management of neuropathic pain: NeuPSIG recommendations.

Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD; International Association for the Study of Pain Neuropathic Pain Special Interest Group.

Pain. 2013 Nov;154(11):2249-61. doi: 10.1016/j.pain.2013.06.004. Epub 2013 Jun 6. Review.

13.

Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.

Adler JJ, Heller BL, Bringman LR, Ranahan WP, Cocklin RR, Goebl MG, Oh M, Lim HS, Ingham RJ, Wells CD.

J Biol Chem. 2013 May 24;288(21):15181-93. doi: 10.1074/jbc.M112.446534. Epub 2013 Apr 5.

14.

LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap.

Nguyen HB, Babcock JT, Wells CD, Quilliam LA.

Oncogene. 2013 Aug 29;32(35):4100-9. doi: 10.1038/onc.2012.431. Epub 2012 Oct 1.

15.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

17.

Delamanid for multidrug-resistant pulmonary tuberculosis.

Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.

N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.

18.

Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.

Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA.

Am J Respir Crit Care Med. 2012 Aug 1;186(3):273-9. doi: 10.1164/rccm.201111-2076OC. Epub 2012 May 3.

PMID:
22561962
19.

OCRL localizes to the primary cilium: a new role for cilia in Lowe syndrome.

Luo N, West CC, Murga-Zamalloa CA, Sun L, Anderson RM, Wells CD, Weinreb RN, Travers JB, Khanna H, Sun Y.

Hum Mol Genet. 2012 Aug 1;21(15):3333-44. doi: 10.1093/hmg/dds163. Epub 2012 Apr 27.

20.

Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.

PMID:
22283887
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk